Noile-Immune Biotech Inc. (4893)
Market Closed
12 Aug, 06:00
JPX JPX Primary ¥
140. 00
-1
-0.7092%
¥
7.01B Market Cap
- P/E Ratio
- Div Yield
27,400 Volume
- Eps
¥ 141
Previous Close Want to track 4893 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4893 closed today lower at ¥140, a decrease of -0.7092% from yesterday's close, completing a monthly increase of 13.8211% or ¥17. Over the past 12 months, 4893 stock gained 4.4776%.
4893 is not paying dividends to its shareholders.
The last earnings report, released on May 19, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Noile-Immune Biotech Inc. (4893) FAQ
What is the stock price today?
The current price is ¥140.00.
On which exchange is it traded?
Noile-Immune Biotech Inc. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4893.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 7.01B.
Has Noile-Immune Biotech Inc. ever had a stock split?
No, there has never been a stock split.
Noile-Immune Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Koji Tamada M.D., Ph.D. CEO | JPX Exchange | JP3759560000 ISIN |
| Japan Country | 23 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Noile-Immune Biotech Inc. is at the forefront of innovative cancer treatments, specializing in the research and development of CAR-T cell therapies. Since its inception in 2015, Noile-Immune Biotech has dedicated itself to harnessing the power of the immune system to combat cancer. The company is based in Minato, Japan, where it operates with a vision to revolutionize cancer immunotherapy globally. Through cutting-edge research and development, Noile-Immune Biotech Inc. aims to create effective, targeted treatments that offer new hope to cancer patients worldwide.
Products and Services
Noile-Immune Biotech Inc. offers a range of products and services focused on CAR-T cell technology for cancer treatment, including:
- Research and Development of CAR-T Therapies: Noile-Immune Biotech is dedicated to the innovation and improvement of CAR-T cell therapies. These therapies are designed to modify a patient's T-cells to better recognize and attack cancer cells, offering a potent and personalized treatment option for various types of cancer.
- Clinical Trials: The company conducts rigorous clinical trials to assess the efficacy and safety of its CAR-T cell therapies. By participating in these trials, Noile-Immune Biotech not only advances the development of its treatments but also contributes valuable data to the scientific community, paving the way for future breakthroughs in cancer care.
Contact Information
Address: T&G Hamamatsucho Building
Phone: 81 3 5843 7819
Website: https://www.noile-immune.com
